Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 mars 2026 09h00 HE | Source: Egg Medical, Inc.

Egg Medical Presents CRT 2026 Data Demonstrating a Responsible Path to Light Lead and Lead-Apron Free Protection

Egg Medical's Late-Breaker at CRT 2026 proves the EggNest™ reduces scatter radiation, allowing the interventional team to safely work lead-apron free.
10 mars 2026 08h45 HE | Source: Propanc Biopharma, Inc.

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients
10 mars 2026 04h30 HE | Source: Kainova Therapeutics

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.
05 mars 2026 08h00 HE | Source: Tangram Therapeutics PLC

Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine

Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH patients Initial data anticipated H2 2026 LONDON, March 05, 2026 ...
05 mars 2026 07h00 HE | Source: Herantis Pharma plc

Herantis Pharma releases 2H and FY 2025 report today

Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies...
05 mars 2026 05h00 HE | Source: Priavoid GmbH

Priavoid to Present Initial Phase 2 Safety Data for Alzheimer‘s and Preclinical PoC for Parkinson‘s Programs at AD/PD™ 2026

Dusseldorf, Germany, March 5, 2026 - Priavoid GmbH (“Priavoid”) today announced it will present promising initial safety data from the ongoing Phase 2 trial (PRImus-AD, NCT06182085) evaluating its...
05 mars 2026 03h03 HE | Source: Nxera Pharma

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development...
04 mars 2026 10h57 HE | Source: FemPulse

FemPulse Pivotal Study Selected For Presentation at the American Urological Association Annual Conference

SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- FemPulse™, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today that the Company’s pivotal...
04 mars 2026 02h30 HE | Source: Tensive

Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy

Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology (ECR) Ultrasound follow-up documented predictable scaffold bioresorption and...
03 mars 2026 09h15 HE | Source: Psyence Biomedical Ltd.

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

Page suivante